NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $28.50 Consensus PT from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned a consensus rating of “Buy” from the five ratings firms that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $28.50.

NRXP has been the subject of several recent research reports. Ascendiant Capital Markets boosted their target price on shares of NRx Pharmaceuticals from $45.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. D. Boral Capital reaffirmed a “buy” rating and set a $31.00 target price on shares of NRx Pharmaceuticals in a report on Friday, June 20th. BTIG Research began coverage on shares of NRx Pharmaceuticals in a research note on Wednesday, April 2nd. They set a “buy” rating and a $18.00 target price on the stock. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday, March 20th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sassicaia Capital Advisers LLC acquired a new stake in NRx Pharmaceuticals in the 4th quarter worth approximately $33,000. Squarepoint Ops LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter worth $56,000. Millennium Management LLC acquired a new position in shares of NRx Pharmaceuticals during the 4th quarter valued at about $61,000. Anson Funds Management LP boosted its position in shares of NRx Pharmaceuticals by 30.3% during the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after acquiring an additional 43,135 shares during the last quarter. Finally, AdvisorShares Investments LLC increased its stake in NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after purchasing an additional 180,229 shares during the period. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Stock Up 0.7%

NRXP opened at $3.03 on Friday. The stock has a market cap of $52.39 million, a P/E ratio of -1.51 and a beta of 1.59. The company has a fifty day simple moving average of $3.01 and a 200 day simple moving average of $2.71. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Thursday, May 15th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.14 million. On average, equities research analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.